AVDL vs. CRNX, ZLAB, MTSR, DNLI, XENE, MOR, TWST, VCEL, CPRX, and MLTX
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Avadel Pharmaceuticals presently has a consensus target price of $19.88, indicating a potential upside of 136.33%. Crinetics Pharmaceuticals has a consensus target price of $72.64, indicating a potential upside of 93.82%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Avadel Pharmaceuticals' return on equity.
Avadel Pharmaceuticals received 189 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.30% of users gave Crinetics Pharmaceuticals an outperform vote while only 66.35% of users gave Avadel Pharmaceuticals an outperform vote.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Avadel Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
Avadel Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avadel Pharmaceuticals had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Avadel Pharmaceuticals and 2 mentions for Crinetics Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.26 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media.
Summary
Avadel Pharmaceuticals and Crinetics Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free AVDL Stock Alerts